A Meta-Analysis of Placebo-Controlled Clinical Trials Assessing the Efficacy and Safety of Incretin-Based Medications in Patients with Type 2 Diabetes
The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Abstract
Aims: A systematic review of the literature, in combination with a meta-analysis of randomized controlled trials comparing treatments with placebo, was conducted to provide an update on the clinical efficacy and safety of incretin-based medications in adult patients with type 2 diabetes. Methods: A literature search (2000–2009) identified 38 placebo-controlled trials (phase II or later – parallel design) comparing exenatide (n = 8), liraglutide (n = 7), vildagliptin (n = 11) and sitagliptin (n = 12) with placebo. Outcomes were change from baseline in HbA 1c and in weight, and the number of patient-reported hypoglycemic episodes. HbA 1c and weight outcomes were analyzed as weighted mean differences (WMD), and the number of hypoglycemic episodes as relative risks (RR). Results: Patients receiving liraglutide showed greater reduction in HbA 1c in comparison to placebo (WMD = –1.03, 95% confidence interval, CI = –1.16 to –0.90, p < 0.001) than those on sitagliptin (WMD = –0.79, 95% CI = –0.93 to –0.65, p < 0.001), exenatide (WMD = –0.75, 95% CI = –0.83 to –0.67, p < 0.001) or vildagliptin (WMD = –0.67, 95% CI = –0.83 to –0.52, p < 0.001). Weight was statistically significantly negatively associated with exenatide (WMD = –1.10, 95% CI = –1.32 to –0.87, p < 0.001) and positively associated with sitagliptin (WMD = 0.60, 95% CI = 0.33–0.87, p < 0.001) and vildagliptin (WMD = 0.56, 95% CI = 0.27–0.84, p < 0.001). The number of patient-reported hypoglycemic episodes was statistically significantly associated with the use of sitagliptin (RR = 2.56, 95% CI = 1.23–5.33, p = 0.01) and exenatide (RR = 2.40, 95% CI = 1.30–4.11, p = 0.002). Conclusion: Incretin-based therapies are effective in glycemic control and also offer other advantages such as weight loss (exenatide and liraglutide). This may have an important impact on patient adherence to medication.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Economic Costs of Diabetes in the U.S. in 2002
American Diabetes Association (2003) · Diabetes Care · doi:10.2337/diacare.26.3.917 · Cited by 4,147 · cited 1×
“The total estimated cost of diabetes in the USA in 2007 was USD 174 billion, including USD 116 billion in excess medical expenditures and USD 58 billion in reduced national productivity [”
BackgroundDeFronzo, R. A., Ratner, R. E., Han, J., Kim, D. D., Fineman, M. S., & Baron, A. D. (2005) · Diabetes Care · doi:10.2337/diacare.28.5.1092 · Cited by 1,559
Buse, J. B., Henry, R. R., Han, J., Kim, D. D., Fineman, M. S., Baron, A. D., & for the Exenatide-113 Clinical Study Group (2004) · Diabetes Care · doi:10.2337/diacare.27.11.2628 · Cited by 1,346
Kendall, D. M., Riddle, M. C., Rosenstock, J., Zhuang, D., Kim, D. D., Fineman, M. S., & Baron, A. D. (2005) · Diabetes Care · doi:10.2337/diacare.28.5.1083 · Cited by 1,177
Nauck, M., Frid, A., Hermansen, K., Shah, N. S., Tankova, T., Mitha, I. H., Zdravkovic, M., Düring, M., Matthews, D. R., & for the LEAD-2 Study Group (2009) · Diabetes Care · doi:10.2337/dc08-1355 · Cited by 1,129
Zinman, B., Gerich, J., Buse, J. B., Lewin, A., Schwartz, S., Raskin, P., Hale, P. M., Zdravkovic, M., Blonde, L., & the LEAD-4 Study Investigators (2009) · Diabetes Care · doi:10.2337/dc08-2124 · Cited by 848
Charbonnel, B., Karasik, A., Liu, J., Wu, M., Meininger, G., & for the Sitagliptin Study 020 Group (2006) · Diabetes Care · doi:10.2337/dc06-0706 · Cited by 790
Meta-analysis: Potentials and promise
Egger, M., & Smith, G. D. (1997) · BMJ · doi:10.1136/bmj.315.7119.1371 · Cited by 646
Raz, I., Hanefeld, M., Xu, L., Caria, C., Williams-Herman, D., Khatami, H., & Sitagliptin Study 023 Group (2006) · Diabetologia · doi:10.1007/s00125-006-0416-z · Cited by 614
Ahrén, B., Gomis, R., Standl, E., Mills, D., & Schweizer, A. (2004) · Diabetes Care · doi:10.2337/diacare.27.12.2874 · Cited by 487
Moretto, T. J., Milton, D. R., Ridge, T. D., MacConell, L. A., Okerson, T., Wolka, A. M., & Brodows, R. G. (2008) · Clinical Therapeutics · doi:10.1016/j.clinthera.2008.08.006 · Cited by 350
Cited by
Hippocampal insulin resistance and cognitive dysfunction
Biessels, G. J., & Reagan, L. P. (2015) · Nature Reviews Neuroscience · doi:10.1038/nrn4019 · Cited by 537
Matching-Adjusted Indirect Comparisons: A New Tool for Timely Comparative Effectiveness Research
Signorovitch, J. E., Sikirica, V., Erder, M. H., Xie, J., Lu, M., Hodgkins, P. S., Betts, K. A., & Wu, E. Q. (2012) · Value in Health · doi:10.1016/j.jval.2012.05.004 · Cited by 505
Karagiannis, T., Paschos, P., Paletas, K., Matthews, D. R., & Tsapas, A. (2012) · BMJ · doi:10.1136/bmj.e1369 · Cited by 435
Robinson, L. E., Holt, T. A., Rees, K., Randeva, H. S., & O'Hare, J. P. (2013) · BMJ Open · doi:10.1136/bmjopen-2012-001986 · Cited by 296
“A recent review of liraglutide by Buse acknowledges the effect,[14] but a meta-analysis on safety of incretin based therapies published in 2010 did not mention heart rate,[15] nor does an overview of the LEAD trials of liraglutide by Blonde and RussellJones.”
BackgroundCardiovascular effects of gliptins
Scheen, A. J. (2013) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2012.183 · Cited by 175
Metadata
- Authors
- Fakhoury, W. K. H., LeReun, C., & Wright, D.
- Venue
- Pharmacology
- Publisher
- S. Karger AG
- Published
- 2010
- Volume
- 86
- Issue
- 1
- Pages
- 44-57
- ISSN
- 0031-7012 (ISSN-L)
- 1423-0313
- OpenAlex
- W2058468402
- Cited by
- 110
- References
- 11
- FWCI
- 2.85
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.